Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OPK 
Opko Health Inc (OPK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OPK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.62
1 Year Target Price $3.62
| 2 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.27% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.19B USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 7 | Beta 1.5 | 52 Weeks Range 1.11 - 2.04 | Updated Date 10/17/2025 |
52 Weeks Range 1.11 - 2.04 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.68% | Operating Margin (TTM) -38.25% |
Management Effectiveness
Return on Assets (TTM) -8.46% | Return on Equity (TTM) -13.16% |
Valuation
Trailing PE - | Forward PE 64.52 | Enterprise Value 1346447481 | Price to Sales(TTM) 1.79 |
Enterprise Value 1346447481 | Price to Sales(TTM) 1.79 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA 22.58 | Shares Outstanding 793782780 | Shares Floating 377046821 |
Shares Outstanding 793782780 | Shares Floating 377046821 | ||
Percent Insiders 46.82 | Percent Institutions 26.3 |
Upturn AI SWOT
Opko Health Inc
Company Overview
History and Background
Opko Health Inc. was founded in 1991 as IVAX Corporation by Phillip Frost. It later changed its name to Opko Health and has focused on diagnostics, pharmaceuticals, and biologics.
Core Business Areas
- Diagnostics: Clinical laboratory testing services, including BioReference Laboratories, offering a wide range of diagnostic tests.
- Pharmaceuticals: Development and commercialization of pharmaceutical products and technologies.
- Biologics: Research and development of biologic therapies, including Factor VIIa-CTP for hemophilia A and B.
Leadership and Structure
Phillip Frost is the Chairman and CEO. The company has a board of directors and operates with functional departments across its business segments.
Top Products and Market Share
Key Offerings
- BioReference Laboratories: Provides diagnostic testing services. Competitors include Labcorp (LH) and Quest Diagnostics (DGX). Revenue contributes a significant portion of Opko's overall sales, but specific market share data fluctuates and is challenging to pinpoint precisely.
- Rayaldee: A treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Competitors include Amgen (AMGN) and other phosphate binder manufacturers. Rayaldee revenue, while important, faces competition and market dynamics impacting its precise market share.
- 4Kscore Test: A blood test to assess a manu2019s risk of aggressive prostate cancer. Competitors include Genomic Health (Exact Sciences EXAS) with their Oncotype DX Prostate test. Market share data for 4Kscore is not consistently reported and is a smaller segment of Opko's revenue.
Market Dynamics
Industry Overview
The diagnostics, pharmaceutical, and biologics industries are characterized by intense competition, technological advancements, regulatory hurdles, and evolving healthcare landscapes.
Positioning
Opko Health is positioned as a diversified healthcare company with a mix of diagnostic services, pharmaceutical products, and biologic development. Its competitive advantages include diagnostic network and innovative products in niche markets.
Total Addressable Market (TAM)
TAM for diagnostics, pharmaceuticals, and biologics is multi-billion dollar and is constantly increasing due to new innovations. Opko holds a smaller portion of this TAM.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Established diagnostic network (BioReference Laboratories)
- Experienced leadership
- Proprietary technologies
Weaknesses
- Inconsistent profitability
- High debt levels
- Dependence on key products
- Regulatory risks
Opportunities
- Expanding diagnostic services
- Strategic acquisitions
- New product launches
- Partnerships and collaborations
Threats
- Intense competition
- Generic erosion
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- LH
- DGX
- AMGN
- EXAS
Competitive Landscape
Opko Health faces intense competition from larger, more established players in its various business segments. Success depends on innovation, effective marketing, and strategic execution.
Major Acquisitions
BioReference Laboratories
- Year: 2010
- Acquisition Price (USD millions): 1470
- Strategic Rationale: Expanded Opko's diagnostic testing capabilities and established a significant revenue stream.
Growth Trajectory and Initiatives
Historical Growth: Opko's growth has been a mix of organic expansion and acquisitions, with varying degrees of success.
Future Projections: Future growth projections are contingent on successful product launches, acquisitions, and improved financial performance. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives have included restructuring efforts, new product development, and strategic partnerships.
Summary
Opko Health is a diversified healthcare company with a mix of diagnostic services, pharmaceutical products, and biologic development. The company's BioReference Laboratories provides a strong revenue stream, but inconsistent profitability and high debt remain challenges. Future success hinges on new product launches and strategic execution in a competitive landscape. There is also the matter of regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Financial News Outlets
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opko Health Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1995-11-02 | Chairman & CEO Dr. Phillip Frost M.D., Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2997 | Website https://www.opko.com |
Full time employees 2997 | Website https://www.opko.com | ||
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.